Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
The European Commission has approved ENFLONSIA (clesrovimab) as the first RSV preventive option for infants in the EU.
Therapeutic Area
Therapeutic area intelligence for Respiratory Syncytial Virus (RSV) with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.